Skip to main content
Industrial Research And Consultancy Centre

Process Development for the synthesis of Amino Acid Adenosine-Sulfamoyl Conjugates and uses thereof

 

The present technology relates to the development of novel larvicidal agents targeting aminoacyl-tRNA synthetases (aaRS), which are essential enzymes involved in protein synthesis in mosquito larvae. By selectively inhibiting aaRS, the technology introduces a unique mechanism of action distinct from the conventional larvicides that primarily target the nervous system or developmental pathways. This approach aims to overcome the growing challenge of insecticide resistance while minimising adverse effects on non-target organisms and the environment. Preliminary biological studies have identified promising lead compounds with larvicidal potential against malaria vectors. The technology, therefore, offers a sustainable and innovative strategy for next-generation mosquito control and malaria prevention.

 

Malaria continues to pose a significant global health burden, particularly in tropical and subtropical regions. Existing larvicides used for mosquito control primarily target the nervous system or developmental pathways and have shown reduced efficacy due to the emergence of resistance in mosquito populations. Additionally, concerns regarding environmental toxicity and non-target effects limit their long-term sustainability. Therefore, there is an urgent need to identify novel molecular targets with distinct mechanisms of action for the development of safe, selective, and effective larvicides.

 

aaRS enzymes are involved in the synthesis of protein. Targeting aminoacyl-tRNA synthetases (aaRS) in malaria vector larvae can disrupt protein synthesis, ultimately leading to larval death. Many aaRS inhibitors are reported as potential antibacterial compounds. The same strategy can be repurposed for controlling the growth of malaria larvae. Therefore, our technology employs aaRS as novel molecular targets for mosquito larval control, introducing a mechanism of action distinct from that of conventional larvicides. By inhibiting protein synthesis in mosquito larvae, this approach has the potential to overcome existing larvicide resistance and reduce the likelihood of cross-resistance. The strategy further enables the development of selective inhibitors with minimal impact on non-target organisms, thereby offering an environmentally safer and sustainable solution for malaria vector management. The proof of concept comes from the paper ‘The Journal of Infectious Diseases, Volume 232, Issue 1, 15 July 2025, Pages 255–266’, wherein HFG and L-95 compounds are shown to target malarial vector prolyl tRNA synthetase and acting as a potential larvicidal candidates.

 

The current prototype comprises lead compounds targeting phenylalanyl-tRNA synthetases (PheRS) and lysyl-tRNA synthetases (LysRS) of Anopheles culicifacies, a mosquito species associated with more than 60% of malaria transmission in India. Biochemical and biophysical studies have been conducted using the recombinant proteins AcFRS and AcKRS to evaluate the inhibitory efficiency of the lead molecules. AMS-Phe and AMS-K were assessed against AcFRS and AcKRS, respectively, using a concentration-dependent aminoacylation inhibition with the malachite green assay. The half-maximal inhibitory concentration (IC50) of AMS-Phe and AMS-K was 119 nM and 80 nM, respectively (Figure 1), highlighting their strong potency against their respective Anopheles target proteins. To assess the larvicidal efficacy of AMS derivatives, a systematic assay was conducted using third-instar larvae of Anopheles culicifacies. Groups of 30 larvae were exposed to varying concentrations of AMS-Phe and AMS-K, ranging from 25 to 400 μM. After treatment, larval mortality was recorded at 24-hour intervals over a period of three days to evaluate the compound’s impact across different dosages and durations. The data revealed a strong dose-dependent effect, with AMS-Phe and AMS-K exhibiting larvicidal activity. Notably, the compounds achieved a 50% lethal concentration (LC50) of 71 μM for AMS-Phe (Figure 2), in the initial 24 h. The clear larvicidal activity suggests that it holds promise as an effective tool for directly targeting and disrupting mosquito populations during their early developmental stages. This highlights AMS-Phe’s potential as a valuable candidate for integrated vector control strategies aiming to mitigate the spread of mosquito-borne disease. The lead molecules are currently undergoing further optimisation and biological validation to enhance potency.

 

The development of aaRS-targeted larvicides has the potential to significantly strengthen malaria control programs by reducing mosquito populations and interrupting disease transmission. By employing a novel mechanism of action distinct from conventional larvicides, this technology may help overcome the growing challenge of insecticide resistance in mosquito vectors. Successful implementation of this technology could improve public health outcomes, particularly in malaria-endemic regions, by reducing disease incidence and associated mortality. In addition, the technology provides a novel approach for vector management strategies and translation of academic research into practical societal benefits.

 

The technology has potential applications in mosquito vector control programs aimed at combating malaria and other mosquito-borne diseases. By targeting aminoacyl-tRNA synthetases (aaRS), the developed compounds may serve as next-generation larvicides for use in public health interventions and integrated vector management strategies. The approach may also be extended to control multiple mosquito species causing other severe infectious diseases such as dengue and chikungunya. The technology is of interest to industries involved in agrochemicals, biotechnology, pharmaceuticals, and vector control product development. Furthermore, the platform may facilitate collaborations with government agencies and industrial partners for large-scale deployment and commercialisation of sustainable mosquito control solutions.

Faculty
Prof. Pradeepkumar P. I.
Department
Chemistry
Application Number
202521116198
Date of filing
For More Information :
Technology readiness level
4